Solid-phase nucleic acid synthesis method
By adjusting the concentration of nucleotide monomers and adding activators, the nucleic acid synthesis cycle steps of solid-phase phosphoramidite method are optimized, and the problems of high and low efficiency of nucleic acid synthesis are solved, and high-quality and low-cost nucleic acid synthesis are achieved. .
Patent Information
- Application Number
- CN202411043435.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-15
AI Technical Summary
Existing high-throughput nucleic acid synthesis equipment is costly, especially the synthesis of monomers of modified probes, fluorescently labeled nucleic acids and RNA. The synthesis efficiency of solid-phase phosphoramidite method is low during long-chain synthesis, and the high monomer concentration leads to synthesis quality. Not good.
By using solid-phase phosphoramidite method, the final concentration of nucleotide monomers is adjusted to 0.005-0.025 mol/L, and the coupling reaction is added to the activators such as ETT and BTT, and the reaction conditions such as time and solvent ratio are controlled to control the reaction conditions, so as to Optimize the deprotection, coupling, capping and oxidation reactions of the synthesis cycle steps.
It effectively reduces the cost of nucleic acid synthesis, improves the synthesis efficiency and quality, and reduces the cost of a single base from more than 1 yuan to 0.02 yuan/nt, ensuring the high quality and high purity of nucleic acids.
Smart Images

Figure CN118955594A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of nucleic acid synthesis, and in particular to a solid phase nucleic acid synthesis method. Background Art
[0002] At present, nucleic acid high-throughput synthesis equipment is mainly imported, the synthesis scheme and the amount of synthetic reagents are fixed and single, and the cost of synthesizing bases is high, especially for modified probes, fluorescently labeled nucleic acids, RNA and monomers with special structures. The nucleic acid synthesis method is the solid phase phosphoramidite method, and its main synthesis process is that a synthesis cycle (referring to the extension of a base) includes four steps. The first step is deprotection, that is, treating the nucleoside with a protective group with benzenesulfonic acid or trichloroacetic acid to remove the dimethoxytrityl (DMTr) at the 5' end and expose the 5'OH. The second step is the coupling reaction, adding a nucleoside activated by tetrazole to couple it with the 5'OH of the previous nucleoside. The third step is the capping reaction, adding acetic anhydride and dimethylaminopyridine to acetylate the oligonucleotide chain that did not participate in the reaction, which is conducive to purifying the required full-length DNA fragment. The fourth step is the oxidation reaction, adding an oxidizing agent such as iodine solution to convert the phosphite triester into a more stable phosphotriester. After completing a synthesis cycle, each nucleotide chain on the carrier will increase by one base and will always be fixed on the solid phase carrier. Excess unreacted products or decomposition products are removed by filtration or washing. When the entire chain reaches a predetermined length, it is cut from the solid phase support and the protecting group is removed (aminolysis), and then the desired final product is obtained by separation and purification. In the above column solid phase synthesis, the monomer concentration is 0.06-0.1M by default, and the monomer consumption exceeds 100 equivalents, which is much greater than the theoretical consumption value. When the synthesized oligo is longer, the synthesis efficiency will be significantly reduced, and the synthesis quality will be low. Summary of the invention
[0003] Therefore, the technical problem to be solved by the present invention is to provide a solid-phase nucleic acid synthesis method, which can synthesize nucleic acids with lower monomer concentration and higher synthesis quality, and can effectively reduce the cost of nucleic acid synthesis.
[0004] To this end, the present invention provides the following technical solutions:
[0005] A solid phase nucleic acid synthesis method, which adopts solid phase phosphoramidite method, comprises synthesis reaction cycle steps, each synthesis reaction cycle comprises deprotection, coupling reaction, capping reaction and oxidation reaction;
[0006] In the coupling reaction, the final concentration of the added nucleotide monomer solution is 0.005-0.025 mol / L.
[0007] Optionally, in the coupling reaction, an activator is added at the same time as the nucleotide monomer solution; the activator is a solution containing 0.25-0.6 mol / L ETT, 0.25-0.6 mol / L BTT, and 0.1-1% by mass of nitrogen-methylimidazole;
[0008] Optionally, the activator is a solution containing 0.25 mol / L ETT, 0.25 mol / L BTT, and 0.1-1% by mass of nitrogen-methylimidazole;
[0009] Optionally, the volume of the activator added is 1.2-1.5 times the volume of the nucleotide monomer solution added.
[0010] Optionally, the reaction conditions of the coupling reaction are: reaction time 30 s to 2 min, preferably 40 s.
[0011] Optionally, in the deprotection step, 3-8CV of a DMT deprotection solution having a mass volume ratio of 2.5-3.5% is added, the reaction is carried out for 20s-1min, and the step is repeated once;
[0012] Preferably, the 2.5-3.5% DMT deprotection solution is a solution containing 2.5-3.5% TCA, DCA and / or p-toluenesulfonic acid in a mass volume ratio;
[0013] Preferably, 4CV of a 3% TCA solution by mass volume is added, reacted for 20 seconds, and the step is repeated once.
[0014] Optionally, in the capping reaction, 0.5-2CV of capa solution and 0.5-2CV of capb solution are added, and the reaction is carried out for 10s-1min; the capa solution is a tetrahydrofuran solution containing 1-20v / v% acetic anhydride; the capb solution is a solution of tetrahydrofuran, pyridine and nitrogen methylimidazole mixed in a volume ratio of 64-84:1-20:6-26;
[0015] Preferably, 1CV of capa solution and 1CV of capb solution are added and reacted for 30s; the capa solution is a tetrahydrofuran solution containing 10v / v% acetic anhydride; the capb solution is a solution of tetrahydrofuran, pyridine and nitrogen-methylimidazole mixed in a volume ratio of 74:10:16.
[0016] Optionally, in the oxidation reaction, 1.5-4CV of iodine solution is added and the reaction is carried out for 10s-1min; the concentration of iodine in the iodine solution is 0.02-0.1mol / L, and the solvent is a solution of pyridine, water and tetrahydrofuran mixed in a volume ratio of 15-25:5-15:65-75;
[0017] Preferably, 2CV of iodine solution is added and the reaction is carried out for 30s; the concentration of iodine in the iodine solution is 0.025 mol / L, and the solvent is a solution of pyridine, water and tetrahydrofuran mixed in a volume ratio of 20:10:70.
[0018] Optionally, before the synthesis reaction cycle step begins, a carrier pretreatment step is also included, first washing the carrier twice with an organic solvent, each time for 3-10CV; then adding 0.5-2CV of capa solution and 0.5-2CV of capb solution to the carrier, reacting for 10s-1min; then washing the carrier twice with an organic solvent, each time for 3-10CV; then adding 3-8CV of DMT deprotection solution with a mass volume ratio of 2.5-3.5% to the carrier, reacting for 20s-1min, and repeating this step once;
[0019] Optionally, the carrier is first washed with an organic solvent for 2 times, 6CV each time; then 1CV of capa solution and 1CV of capb solution are added to the carrier, and the reaction is carried out for 30 seconds; then the carrier is washed with an organic solvent for 2 times, 6CV each time; then 4CV of DMT deprotection solution with a mass volume ratio of 2.5-3.5% is added to the carrier, and the reaction is carried out for 30 seconds, and the step is repeated once;
[0020] Optionally, the organic solvent is acetonitrile, dichloromethane or methanol, preferably acetonitrile;
[0021] Optionally, the capa solution is a tetrahydrofuran solution containing 1-20 v / v% acetic anhydride, preferably, a tetrahydrofuran solution containing 10 v / v% acetic anhydride;
[0022] Optionally, the capb solution is a solution in which tetrahydrofuran, pyridine and nitrogen-methylimidazole are mixed in a volume ratio of 64-84:1-20:6-26. Preferably, the capb solution is a solution in which tetrahydrofuran, pyridine and nitrogen-methylimidazole are mixed in a volume ratio of 74:10:16.
[0023] Optionally, the 2.5-3.5% DMT deprotection solution is a solution containing 2.5-3.5% TCA, DCA and / or p-toluenesulfonic acid in a mass volume ratio, preferably a 3% TCA solution in a mass volume ratio.
[0024] Optionally, after the synthesis reaction cycle step is completed, the step further includes adding 3-8CV of a DMT deprotection solution with a mass volume ratio of 2.5-3.5% to the carrier, repeating the step twice, each reaction lasting 20s-1min, then washing with an organic solvent, performing gas phase ammonolysis elution, and detecting;
[0025] Optionally, the 2.5-3.5% DMT deprotection solution is a solution containing 3% by mass volume of TCA, DCA and / or p-toluenesulfonic acid;
[0026] Optionally, the organic solvent is acetonitrile, DCM or methanol.
[0027] Optionally, after the synthesis is completed, a post-treatment step is further included: adding 8CV of a 3% TCA solution by mass volume ratio to the carrier, repeating the step twice, reacting for 30s each time, adding 3-10CV of acetonitrile for washing, washing twice, adding 1-10v / v% acetonitrile aqueous solution for washing 5-20CV, washing three times; aminolysis: adding 1CV of triethylamine (analytical grade) to the synthesis column, adding 20-50ml of ammonia water (national standard mass percentage concentration is 25-28%) to the aminolysis box, 5°C to 105°C, 1-2 hours, taking out after the aminolysis, cooling, adding 90-100% acetonitrile aqueous solution for washing 5-20CV, washing three times, adding 5-20CV of pure water for elution and collection;
[0028] Optionally, add 10 v / v% acetonitrile aqueous solution for washing for 10 CV;
[0029] Optionally, add 90 v / v% acetonitrile aqueous solution to wash for 10 CV;
[0030] Optionally, incubate at 95°C for 1.5 hours.
[0031] Optionally, the carrier is a granular CPG carrier with a particle size of 50-100 microns or a cylindrical FRITS carrier;
[0032] Optional, 30ml of ammonia water.
[0033] The technical solution of the present invention has the following advantages:
[0034] 1. A solid phase nucleic acid synthesis method provided by the present invention adopts a solid phase phosphoramidite method for synthesis, including synthesis reaction cycle steps, each synthesis reaction cycle including deprotection, coupling reaction, capping reaction and oxidation reaction; in the coupling reaction, the concentration of the added nucleotide monomer is 0.005-0.025 mol / L; the present invention has found that by controlling the concentration of the added nucleotide monomer, while ensuring the quality of nucleic acid synthesis (OD260 average yield meets>40%, MS (mass spectrometry) deviation meets 0.05% (mass spectrometry purity>50%), HPLC (liquid chromatography) meets coupling efficiency>99%), the amount of nucleotide monomer used in the process method or traditional method of DNA synthesis is effectively reduced, and the cost of nucleic acid synthesis is greatly reduced. The price per nt is more than 1 yuan. By using the method of the present invention to effectively synthesize high-quality nucleic acids, the cost of single base synthesis at the nmol level can be reduced to 0.02 yuan / nt.
[0035] 2. The present invention provides a solid-phase nucleic acid synthesis method, wherein the nucleotide monomers are pre-activated by an activator; the activator is a solution containing 0.25-0.6 mol / L ETT, 0.25-0.6 mol / L BTT, and 0.1-1% nitrogen-methylimidazole by mass; the present invention has found that the use of the above-mentioned activator can significantly improve the efficiency of nucleic acid synthesis, wherein the synthesis efficiency is the square root of the purity of the crude product (the square root number is the length of the synthesis), for example, if the purity of the 20nt crude product is 80%, then the corresponding coupling efficiency is 0.8 to the 20th power ≈ 0.988. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0037] Figure 1 is the mass spectrum of sample batch 20240107-A1 in Experimental Example 1 of the present invention;
[0038] Figure 2 is the chromatogram of sample batch 20240107-A1 in Experimental Example 1 of the present invention;
[0039] Figure 3 is the mass spectrum of sample batch 20240101-A1 in Experimental Example 1 of the present invention;
[0040] Figure 4 is the chromatogram of sample batch 20240101-A1 in Experimental Example 1 of the present invention;
[0041] Figure 5 is the mass spectrum of sample batch 20240104-A1 in Experimental Example 1 of the present invention;
[0042] Figure 6 is the chromatogram of sample batch 20240104-A1 in Experimental Example 1 of the present invention;
[0043] Figure 7 is the mass spectrum of sample batch 20240110-A1 in Experimental Example 1 of the present invention;
[0044] Figure 8 is the chromatogram of sample batch 20240110-A1 in Experimental Example 1 of the present invention;
[0045] Fig. 9 is the mass spectrum of sample batch 20240203-A1 in Experimental Example 1 of the present invention;
[0046] Fig.10 It is the chromatogram of sample batch 20240203-A1 in Experimental Example 1 of the present invention. DETAILED DESCRIPTION
[0047] The following examples are provided for a better understanding of the present invention, but are not intended to limit the best mode of implementation, nor to limit the content and protection scope of the present invention. Any product identical or similar to the present invention obtained by anyone under the inspiration of the present invention or by combining the features of the present invention with other prior arts shall fall within the protection scope of the present invention.
[0048] If no specific experimental steps or conditions are specified in the examples, the conventional experimental steps or conditions described in the literature in the field can be used. If no manufacturer is specified for the reagents or instruments used, they are all conventional reagent products that can be obtained commercially.
[0049] The nucleic acid synthesizer used in the following examples is a 96-channel synthesizer, a 25 nmol synthesis column with an air resistance of 50-70 mmHg, purchased from Qingke 192-P;
[0050] The reagent information used in the following examples is shown in Table 1.
[0051] 1. Reagent information:
[0052]
[0053] The Chinese name of ETT is 5-(ethylthio)-1H-tetrazole;
[0054] The Chinese name of BTT is 5-benzylthio-1H-tetrazole;
[0055] The Chinese name of DMT is dimethoxytrityl;
[0056] CV in Chinese means column volume;
[0057] The Chinese name of DCM is dichloromethane.
[0058] Example 1
[0059] The target synthetic sequence length is 80 nt, specifically as follows: 5′-GCTGCAGGTTATCGCACCTGTTCGGTCCACTGTTTCGGTCTTCGGTCC ACTGTTTCGGTCGAGTTTGTGCGCGAGTTTGC-3′, see SEQ ID NO.1.
[0060] Synthesis process:
[0061] (1) Before the synthesis reaction cycle step: add acetonitrile to the synthesis column containing the carrier (25nmol) for 6CV washing, wash twice; then add 1CV of capa solution and 1CV of capb solution to the carrier, react for 30s; then wash the carrier twice with acetonitrile, 6Cv each time, then add 4CV of TCA solution with a mass volume ratio of 3% to the carrier, react for 30s, and repeat this step once. The capa solution is a tetrahydrofuran solution containing 10v / v% acetic anhydride; the capb solution is a solution of tetrahydrofuran, pyridine and nitrogen methyl imidazole mixed in a volume ratio of 74:10:16;
[0062] (2) Synthesis reaction cycle steps:
[0063] 1) Deprotection: Add 4CV of 3% TCA solution by weight volume to the carrier in step (1), react for 20 seconds, and repeat this step once;
[0064] 2) Coupling reaction: To the deprotected carrier in step 1), according to the target synthesis sequence, a nucleotide monomer solution is added, and an activator is added at the same time, the final concentration of the nucleotide monomer is 0.025 mol / L, the activator is a solution containing 0.25 mol / L ETT, 0.25 mol / L BTT and 0.5% nitrogen methylimidazole by mass, the volume of the activator added is 1.3 times the volume of the nucleotide monomer solution added, and the coupling reaction time is 40 s.
[0065] 3) Capping reaction: add 1CV of capa solution and 1CV of capb solution to the carrier in step 2) and react for 30s; the capa solution is a tetrahydrofuran solution containing 10v / v% acetic anhydride; the capb solution is a solution of tetrahydrofuran, pyridine and nitrogen-methylimidazole mixed in a volume ratio of 74:10:16;
[0066] 4) Oxidation reaction: add 2CV of iodine solution to the carrier in step 3) and react for 30 seconds; the iodine concentration in the iodine solution is 0.025 mol / L, and the solvent is a solution of pyridine, water and tetrahydrofuran mixed in a volume ratio of 20:10:70;
[0067] Steps 1) to 4) are a synthesis cycle reaction. After completing a synthesis cycle reaction, each nucleotide chain on the carrier will increase by one base, and then the above steps 1) to 4) are repeated to synthesize according to the target synthesis sequence.
[0068] (3) After the synthesis reaction cycle step (2) is completed, add 8CV of 3% TCA solution by mass volume ratio to the carrier, repeat this step twice, and react for 30s each time; add 8CV of acetonitrile for washing, wash twice; add 10CV of 10v / v% acetonitrile aqueous solution for washing, wash three times; aminolysis: add 1CV of triethylamine (analytical grade) to the synthesis column, add 30ml of ammonia water (national standard mass percentage concentration is 25-28%) to the aminolysis box, place the synthesis column and the aminolysis box in an oven at 95°C for 1.5 hours, take out the carrier to cool after the aminolysis, add 90% acetonitrile aqueous solution for washing for 10CV, wash three times, add 10CV of pure water for elution and collect;
[0069] (4) Detecting the target sequence synthesized in step (3).
[0070] Example 2
[0071] The difference between this embodiment and embodiment 1 is that the length of the target synthetic sequence is 80 nt, specifically as follows: 5'-GCTGCAGGTTATCGCACCTGTTCGGTCCACTGTTTCGGTCTTCGGTC CACTGTTTCGGTCGAGTTTGTGCGCGAGTTTGC-3', see SEQ ID NO.2.
[0072] 2) In the coupling reaction, the final concentration of nucleotide monomers was 0.02 mol / L.
[0073] Example 3
[0074] The difference between this embodiment and embodiment 1 is that the length of the target synthetic sequence is 80 nt, specifically as follows: 5'-GCTGCAGGTTATCGCACCTGTTCGGTCCACTGTTTCGGTCTTCGGTCC ACTGTTTCGGTCGAGTTTGTGCGCGAGTTTGC-3', see SEQ ID NO.3.
[0075] 2) In the coupling reaction, the final concentration of nucleotide monomers was 0.015 mol / L.
[0076] Example 4
[0077] The difference between this embodiment and embodiment 1 is that the length of the target synthetic sequence is 80 nt, specifically as follows: 5'-GCTGCAGGTTATCGCACCTGTTCGGTCCACTGTTTCGGTCTTCGGTCC ACTGTTTCGGTCGAGTTTGTGCGCGAGTTTGC-3', see SEQ ID NO.4.
[0078] 2) In the coupling reaction, the final concentration of nucleotide monomers was 0.01 mol / L.
[0079] Example 5
[0080] The difference between this embodiment and embodiment 1 is that the length of the target synthetic sequence is 80 nt, specifically as follows: 5'-GCTGCAGGTTATCGCACCTGTTCGGTCCACTGTTTCGGTCTTCGGTCC ACTGTTTCGGTCGAGTTTGTGCGCGAGTTTGC-3', see SEQ ID NO.5.
[0081] 2) In the coupling reaction, the final concentration of nucleotide monomers was 0.005 mol / L.
[0082] Example 6
[0083] The difference between this embodiment and embodiment 1 is that the synthesis process is as follows:
[0084] (1) Before the synthesis reaction cycle step: add acetonitrile to the synthesis column containing the carrier (25nmol) for washing for 3CV, wash twice; then add 2CV of capa solution and 2CV of capb solution to the carrier, react for 10s; then wash the carrier twice with acetonitrile, 3CV each time; then add 3CV of TCA solution with a mass volume ratio of 3.5% to the carrier, react for 1min, and repeat this step once. The capa solution is a tetrahydrofuran solution containing 1v / v% acetic anhydride; the capb solution is a solution of tetrahydrofuran, pyridine and nitrogen methyl imidazole mixed in a volume ratio of 84:1:26;
[0085] (2) Synthesis reaction cycle steps:
[0086] 1) Deprotection: Add 8CV of 2.5% TCA solution by mass volume ratio to the carrier in step (1), react for 1 min, and repeat this step once;
[0087] 2) Coupling reaction: To the deprotected carrier in step 1), according to the target synthesis sequence, the corresponding nucleotide monomer solution is added, and the activator is added at the same time, the final concentration of the nucleotide monomer is 0.025 mol / L, the activator is a solution containing 0.6 mol / L ETT, 0.6 mol / L BTT, and 1% nitrogen methylimidazole by mass, the volume of the activator added is 1.2 times the volume of the nucleotide monomer solution added, and the coupling reaction time is 30 s.
[0088] 3) Capping reaction: add 2CV of capa solution and 2CV of capb solution to the carrier in step 2) and react for 10 seconds; the capa solution is a tetrahydrofuran solution containing 1v / v% acetic anhydride; the capb solution is a solution of tetrahydrofuran, pyridine and nitrogen-methylimidazole mixed in a volume ratio of 84:1:26;
[0089] 4) Oxidation reaction: add 1.5CV of iodine solution to the carrier in step 3) and react for 10s; the iodine concentration in the iodine solution is 0.1 mol / L, and the solvent is a solution of pyridine, water and tetrahydrofuran mixed in a volume ratio of 15:5:75;
[0090] Steps 1) to 4) are a synthesis cycle reaction. After completing a synthesis cycle reaction, each nucleotide chain on the carrier will increase by one base, and then the above steps 1) to 4) are repeated to synthesize according to the target synthesis sequence.
[0091] (3) After the synthesis reaction cycle step (2) is completed, add 3CV of 2.5% TCA solution by mass volume ratio to the carrier, repeat this step twice, and react for 1 min each time; add 10CV of acetonitrile for washing, wash twice; add 8v / v% acetonitrile aqueous solution for washing 5CV, wash three times; aminolysis: add 1CV of triethylamine (analytical grade) to the synthesis column, add 20ml of ammonia water (national standard mass percentage concentration is 25-28%) to the aminolysis box, place the synthesis column and the aminolysis box in an oven at 95°C for 1.5 hours, take out the solution after aminolysis, cool it down, add 95% acetonitrile aqueous solution for washing 20CV, wash three times, add 5CV of pure water for elution and collect;
[0092] (4) Detecting the target sequence synthesized in step (3).
[0093] Example 7
[0094] The difference between this embodiment and embodiment 1 is that the synthesis process is as follows:
[0095] (1) Before the synthesis reaction cycle step: add acetonitrile to the synthesis column containing the carrier (25nmol) for washing for 10CV, wash twice; then add 0.5CV of capa solution and 0.5CV of capb solution to the carrier, react for 1min; then wash the carrier twice with acetonitrile, 10CV each time; then add 8CV of TCA solution with a mass volume ratio of 2.5% to the carrier, react for 20s, and repeat this step once. The capa solution is a tetrahydrofuran solution containing 8v / v% acetic anhydride; the capb solution is a solution of tetrahydrofuran, pyridine and nitrogen methyl imidazole mixed in a volume ratio of 64:20:6;
[0096] (2) Synthesis reaction cycle steps:
[0097] 1) Deprotection: Add 3CV of 3.5% TCA solution by mass volume ratio to the carrier in step (1), react for 20 seconds, and repeat this step once;
[0098] 2) Coupling reaction: To the deprotected carrier in step 1), according to the target synthesis sequence, the corresponding nucleotide monomer solution is added, and the activator is added at the same time, the final concentration of the nucleotide monomer is 0.025 mol / L, the activator is a solution containing 0.4 mol / L ETT, 0.4 mol / L BTT and 0.1% nitrogen methylimidazole by mass, the volume of the activator added is 1.5 times the volume of the nucleotide monomer solution added, and the coupling reaction time is 2 min.
[0099] 3) Capping reaction: add 0.5CV of capa solution and 0.5CV of capb solution to the carrier in step 2) and react for 1 min; the capa solution is a tetrahydrofuran solution containing 20v / v% acetic anhydride; the capb solution is a solution of tetrahydrofuran, pyridine and nitrogen-methylimidazole mixed in a volume ratio of 84:1:26;
[0100] 4) Oxidation reaction: add 4CV of iodine solution to the carrier in step 3) and react for 1 min; the iodine concentration in the iodine solution is 0.02 mol / L, and the solvent is a solution of pyridine, water and tetrahydrofuran mixed in a volume ratio of 25:15:65;
[0101] Steps 1) to 4) are a synthesis cycle reaction. After completing a synthesis cycle reaction, each nucleotide chain on the carrier will increase by one base, and then the above steps 1) to 4) are repeated to synthesize according to the target synthesis sequence.
[0102] (3) After the synthesis reaction cycle step (2) is completed, 10CV of TCA solution with a mass volume ratio of 3.5% is added to the carrier, and this step is repeated twice, with each reaction lasting 20s; 3CV of acetonitrile is added for washing, and washing is performed twice; 20CV of 1v / v% acetonitrile aqueous solution is added for washing, and washing is performed three times; aminolysis: 1CV of triethylamine (analytical grade) is added to the synthesis column, and 50ml of ammonia water (the national standard mass percentage concentration is 25-28%) is added to the aminolysis box, and the synthesis column and the aminolysis box are placed in an oven at 95°C for 1.5 hours. After the aminolysis is completed, the carrier is taken out and cooled, and 100% acetonitrile is added for washing for 5CV, and washing is performed three times. 20CV of pure water is added for elution and collection;
[0103] (4) Detecting the target sequence synthesized in step (3).
[0104] Example 8
[0105] The difference between this example and Example 6 is that the target synthetic nucleic acid sequence and the concentration of nucleic acid monomers added in the coupling reaction are replaced by the schemes in Example 2, Example 3, Example 4 or Example 5.
[0106] Example 9
[0107] The difference between this example and Example 7 is that the target synthetic nucleic acid sequence and the concentration of nucleic acid monomers added in the coupling reaction are replaced by the schemes in Example 2, Example 3, Example 4 or Example 5.
[0108] Experimental example
[0109] The target sequences synthesized in Examples 1 to 5 were detected by the following method:
[0110] Color observation: The eluents obtained in Examples 1 to 5 were orange-red, which was normal in color.
[0111] Concentration detection: Collect 10 μL of the eluate and measure the OD value at a wavelength of 260 nm.
[0112] HPLC determination method: Use Waters 2695 chromatograph, the mobile phase is acetonitrile + TEAA system (triethylammonium acetate, 0.05-0.1 mol / L), the chromatographic column is C18, the program is set to 30 min, the flow rate is 0.5-0.8 ml / min, the acetonitrile is increased from 2% to 15%, and about 1000 ng of sampling is carried out for injection analysis. The purity of the synthetic crude product is determined according to the peak shape.
[0113] Mass spectrometry MS detection: Thermo Fisher LTQ is used for detection. The theoretical molecular weight and impurities of the synthesized nucleotide sequence are checked according to the test report issued, and the deviation is within 0.05% to determine the pass.
[0114] Next-generation sequencing: NGS sequencing is performed by Tianjin Qingke Bio-sequencing. An 80nt primer is designed, and the 20nt at both ends are complementary to the primers on the sequencing template. The middle 40nt is a variable sequence. After amplification, the sample is enriched and tested. The general sample size is >3000X. The ratio of the correct number of sequences to the sequencing depth is determined by bioinformatics analysis as the NGS number mutation rate.
[0115] The test results are as follows:
[0116] (1) The concentration test results are as follows:
[0117] Table 2. Concentration test results
[0118]
[0119] (2) Molecular weight and purity detection
[0120] The sample batches in Table 2 were subjected to mass spectrometry MS and HPLC detection, and the detection was carried out three times in parallel, and they were recorded as A1, E6 and H12 respectively. The detection results are shown in the following table. The MS and HPLC graphs are only Figure 1-Figure 10 For example.
[0121] Table 3. Molecular weight and purity test results of Example 1
[0122] Sample batch name Target molecular weight Detection molecular weight Mass Spectrometry Purity HPLC purity 20240107-A1 24622.0000 24623.7 37.37% 62.18% 20240107-E6 24622.0000 24623.4 76.79% 54.81% 20240107-H12 24622.0000 24623.6 71.55% 61.82% 20240108-A1 24622.0000 24624.4 70.73% 67.95% 20240108-E6 24622.0000 24624.7 64.92% 63.46% 20240108-H12 24622.0000 24624.6 71.89% 66.41% 20240109-A1 24622.0000 24623.9 61.41% 60.93% 20240109-E6 24622.0000 24623.7 63.93% 61.58% 20240109-H12 24622.0000 24623.9 77.72% 61.64%
[0123] Table 4. Molecular weight and purity test results of Example 2
[0124] Sample batch name Target molecular weight Detection molecular weight Mass Spectrometry Purity HPLC purity 20240101-A1 24622.0000 24625.1 84.65% 52.41% 20240101-E6 24622.0000 24623.6 66.12% 51.03% 20240101-H12 24622.0000 24623.4 73.38% 52.45% 20240102-A1 24622.0000 24624.1 53.85% 44.99% 20240102-E6 24622.0000 24624.6 67.90% 51.04% 20240102-H12 24622.0000 24623.0 58.01% 47.18%
[0125] Table 5. Molecular weight and purity test results of Example 3
[0126]
[0127]
[0128] Table 6. Molecular weight and purity test results of Example 4
[0129] Sample batch name Target molecular weight Detection molecular weight Mass Spectrometry Purity HPLC purity 20240110-A1 24622.0000 24623.3 79.01% 68.19% 20240110-E6 24622.0000 24624.0 80.03% 68.89% 20240110-H12 24622.0000 24622.8 87.89% 67.90% 20240111-A1 24622.0000 24623.9 85.38% 63.59% 20240111-E6 24622.0000 24623.9 87.90% 61.80% 20240111-H12 24622.0000 24624.8 87.43% 62.97% 20240112-A1 24622.0000 24623.4 83.68% 60.22% 20240112-E6 24622.0000 24622.9 85.17% 68.24% 20240112-H12 24622.0000 24625.1 84.65% 61.75%
[0130] Table 7. Molecular weight and purity test results of Example 5
[0131] Sample batch name Target molecular weight Detection molecular weight Mass Spectrometry Purity HPLC purity 20240203-A1 24622.0000 24625.9 80.65% 67.67% 20240203-E6 24622.0000 24626.1 88.77% 72.17% 20240203-H12 24622.0000 24625.4 81.09% 71.38% 20240204-A1 24622.0000 24626.4 79.81% 74.70% 20240204-E6 24622.0000 24625.7 82.12% 76.99% 20240204-H12 24622.0000 24625.7 84.46% 74.99% 20240205-A1 24622.0000 24625.8 83.62% 66.04% 20240205-E6 24622.0000 24626.7 81.71% 69.67% 20240205-H12 24622.0000 24627.6 85.54% 61.55%
[0132] As can be seen from the table above, the above synthesis results prove that: when the monomer concentration is between 0.005 and 0.025 mol / L, nucleic acid synthesis can be carried out, the UV absorption is normal, the yield is about 50%, the MS target peak is the main peak, and the HPLC purity is about 60%. It meets the national standard for primer quality synthesis.
[0133] (3) The results of the second generation sequencing are as follows:
[0134] Table 8. Next-generation sequencing results
[0135]
[0136]
[0137] In summary, the test result values of different batches corresponding to different monomer concentrations in Tables 2 to 9 above are averaged, and the final synthesis results of different monomer concentrations are compared, where OD / μl corresponds to the volume of the mother solution at OD=1, and the concentration of DNA at OD=1 is generally converted to 33μg / ul, and then the concentration is multiplied by the OD measurement value, and then multiplied by the collected elution volume to obtain the mass of the collected synthetic nucleic acid, and then the mass of the synthetic nucleic acid is divided by the target molecular weight of the synthetic nucleic acid to obtain the molar number of the synthetic nucleic acid, average yield = molar number of synthetic nucleic acid / molar number of carrier × 100%; equivalent = molar number of added nucleic acid monomers / molar number of carriers, for example, 0.025mol / L can be converted to 25nmol / ul, the volume of the added nucleic acid monomer solution is 30ul, and the carrier is 25nmol, then the equivalent is 25*30 / 25=30.
[0138] Table 9. Comparison of synthesis results at different monomer concentrations
[0139]
[0140] Results: When the monomer concentration was reduced to 0.005 mol / L, the nucleic acid yield was reduced to 37%, a year-on-year decrease of about 32%. With the decrease of monomer concentration, the reaction equivalent decreased, the mutation rate and HPLC purity decreased linearly, and the coupling efficiency decreased to below 0.99. The above data proved that the monomer concentration reduced to 0.005 mol / L is the lowest limit for nucleic acid synthesis, and when the monomer concentration is less than 0.005 mol / L, it is not suitable for nucleic acid synthesis.
[0141] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.
Claims
1. A solid phase nucleic acid synthesis method, characterized in that: The method adopts a solid phase phosphoramidite method for synthesis, including synthesis reaction cycle steps, each synthesis reaction cycle including deprotection, coupling reaction, capping reaction and oxidation reaction; In the coupling reaction, the final concentration of the added nucleotide monomer solution is 0.005-0.025 mol / L.
2. The solid phase nucleic acid synthesis method according to claim 1, characterized in that: In the coupling reaction, an activator is added at the same time as the nucleotide monomer solution; the activator is a solution containing 0.25-0.6 mol / L ETT, 0.25-0.6 mol / L BTT, and 0.1-1% by mass of nitrogen-methylimidazole; Optionally, the activator is a solution containing 0.25 mol / L ETT, 0.25 mol / L BTT, and 0.1-1% by mass of nitrogen-methylimidazole; Optionally, the volume of the activator added is 1.2-1.5 times the volume of the nucleotide monomer solution added.
3. The solid phase nucleic acid synthesis method according to claim 1 or 2, characterized in that: The reaction conditions of the coupling reaction are: reaction time 30s to 2min, preferably 40s.
4. The solid phase nucleic acid synthesis method according to any one of claims 1 to 3, characterized in that: In the deprotection step, add 3-8CV of DMT deprotection solution with a mass volume ratio of 2.5-3.5%, react for 20s-1min, and repeat this step once; Preferably, the 2.5-3.5% DMT deprotection solution is a solution containing 2.5-3.5% TCA, DCA and / or p-toluenesulfonic acid in a mass volume ratio; Preferably, 4CV of a 3% TCA solution by mass volume is added, reacted for 20 seconds, and the step is repeated once.
5. The solid phase nucleic acid synthesis method according to any one of claims 1 to 4, characterized in that: In the capping reaction, 0.5-2CV of capa solution and 0.5-2CV of capb solution are added, and the reaction is carried out for 10s-1min; the capa solution is a tetrahydrofuran solution containing 1-20v / v% acetic anhydride; the capb solution is a solution of tetrahydrofuran, pyridine and nitrogen methylimidazole mixed in a volume ratio of 64-84:1-20:6-26; Preferably, 1CV of capa solution and 1CV of capb solution are added and reacted for 30s; the capa solution is a tetrahydrofuran solution containing 10v / v% acetic anhydride; The capb solution is a solution in which tetrahydrofuran, pyridine and nitrogen-methylimidazole are mixed in a volume ratio of 74:10:
16.
6. The solid phase nucleic acid synthesis method according to any one of claims 1 to 5, characterized in that: In the oxidation reaction, 1.5-4CV of iodine solution is added and the reaction is carried out for 10s-1min; the concentration of iodine in the iodine solution is 0.02-0.1mol / L, and the solvent is a solution of pyridine, water and tetrahydrofuran mixed in a volume ratio of 15-25:5-15:65-75; Preferably, 2CV of iodine solution is added and the reaction is carried out for 30 seconds; the concentration of iodine in the iodine solution is 0.025 mol / L, and the solvent is a solution of pyridine, water and tetrahydrofuran mixed in a volume ratio of 20:10:
70.
7. The solid phase nucleic acid synthesis method according to any one of claims 1 to 6, characterized in that: Before the synthesis reaction cycle step starts, the method also includes a carrier pretreatment step, first washing the carrier twice with an organic solvent, each time for 3-10CV; then adding 0.5-2CV of capa solution and 0.5-2CV of capb solution to the carrier, reacting for 10s-1min; then washing the carrier twice with an organic solvent, each time for 3-10CV; then adding 3-8CV of DMT deprotection solution with a mass volume ratio of 2.5-3.5% to the carrier, reacting for 20s-1min, and repeating this step once; Optionally, the carrier is first washed with an organic solvent for 2 times, 6CV each time, and then 1CV of capa solution and 1CV of capb solution are added to the carrier, reacting for 30s, and then the carrier is washed with an organic solvent for 2 times, 6CV each time, and then 4CV of DMT deprotection solution with a mass volume ratio of 2.5-3.5% is added to the carrier, reacting for 30s, and repeating this step once; Optionally, the organic solvent is acetonitrile, dichloromethane or methanol, preferably acetonitrile; Optionally, the capa solution is a tetrahydrofuran solution containing 1-20 v / v% acetic anhydride, preferably, a tetrahydrofuran solution containing 10 v / v% acetic anhydride; Optionally, the capb solution is a solution in which tetrahydrofuran, pyridine and nitrogen-methylimidazole are mixed in a volume ratio of 64-84:1-20:6-26. Preferably, the capb solution is a solution in which tetrahydrofuran, pyridine and nitrogen-methylimidazole are mixed in a volume ratio of 74:10:
16. Optionally, the 2.5-3.5% DMT deprotection solution is a solution containing 2.5-3.5% TCA, DCA and / or p-toluenesulfonic acid in a mass volume ratio, preferably a 3% TCA solution in a mass volume ratio.
8. The solid phase nucleic acid synthesis method according to any one of claims 1 to 7, characterized in that: After the synthesis reaction cycle step is completed, a post-treatment step is also included: adding 3-8CV of DMT deprotection solution with a mass volume ratio of 2.5-3.5% to the carrier, repeating this step twice, each reaction for 20s-1min, then washing with an organic solvent, performing gas phase ammonolysis elution, and detecting; Optionally, the 2.5-3.5% DMT deprotection solution is a solution containing 3% by mass volume of TCA, DCA and / or p-toluenesulfonic acid; Optionally, the organic solvent is acetonitrile, DCM or methanol.
9. The solid phase nucleic acid synthesis method according to claim 8, characterized in that: After the synthesis is completed, the post-treatment step is also included: adding 8CV of 3% TCA solution by mass volume ratio to the carrier, repeating this step twice, each time reacting for 30s; adding 3-10CV of acetonitrile for washing, washing twice; adding 1-10v / v% acetonitrile aqueous solution for washing 5-20CV, washing three times; aminolysis: adding 1CV of triethylamine to the synthesis column, adding 20-50ml of ammonia water to the aminolysis box, and then placing it at 95-105°C for 1-2 hours, taking it out after the aminolysis is completed, cooling it, adding 90-100v / v% acetonitrile aqueous solution for washing 5-20CV, washing three times, adding 5-20CV of pure water for elution and collecting; Optionally, add 10 v / v% acetonitrile aqueous solution for washing for 10 CV; Optionally, add 90 v / v% acetonitrile aqueous solution to wash for 10 CV; Optionally, incubate at 95°C for 1.5 hours.
10. The solid phase nucleic acid synthesis method according to any one of claims 1 to 9, characterized in that: The carrier is a granular CPG carrier with a particle size of 50-100 microns or a cylindrical FRITS carrier.
